Atrial septal defect
An atrial septal defect (ASD) is an opening in the wall between the two upper chambers of the heart. A MeSH scope note describes it as a developmental abnormality of that wall that creates an abnormal communication between the two upper chambers, and lists the types as ostium primum, ostium secundum, sinus venosus and coronary sinus defects. A 2025 open-access review says an ASD is the most common congenital heart defect diagnosed in adulthood, that most children with an isolated ASD have no symptoms, and that signs of adverse effects increase with age, including a higher risk of heart failure, stroke and atrial fibrillation.
Also called ASD · Atrial septal defects
- Condition
- In this atlas
Overview
Technical summary
MeSH descriptor D006344, Heart Septal Defects, Atrial (exact). Its scope note describes developmental abnormalities in any portion of the atrial septum that result in abnormal communications between the two upper chambers of the heart, and lists ostium primum, ostium secundum, sinus venosus and coronary sinus defects. MeSH files Patent Foramen Ovale beneath it; this atlas gives that condition its own page and files it under this one. A 2025 open-access narrative review of ASD and heart rhythm disorders (Biomedicines, CC BY 4.0) says ostium secundum defects are the most frequent type (about 80% of all ASDs) and that patients with an ASD have an increased risk of developing heart failure, stroke, atrial fibrillation and pneumonia, and a reduced life expectancy regardless of closure in childhood or adulthood. MedlinePlus lists septal defects ("hole in the heart") among the most common types of congenital heart defect. The review's rhythm and electrocardiogram findings, its comparison of closed and open defects and its treatment options are not repeated here, and the atlas gives no rule about testing for or closing a defect; closure has its own page. The evidence recorded is descriptive and comes from a scope note, a patient information page and a narrative review, with no study data.
Recognition
A 2025 review says most children with an isolated atrial septal defect have no symptoms and that signs of adverse effects increase with age.
Burden
No burden claims are published.
Claims and evidence
Context People with an atrial septal defect (2025 narrative review)
- Recipient
- Mixed recipients
- Population
- People with an atrial septal defect, children and adults, as the review describes them. The statements come from its abstract and introduction, which draw on the wider literature.
- Care setting
- Not stated for the review as a whole. The review discusses diagnosis, closure and long-term follow-up.
- Geography
- Not stated for the review as a whole.
- Life stage
- Children and adults. The review says most children with an isolated defect have no symptoms and that signs of adverse effects increase with age. This record makes no statement about pregnancy, fetuses or newborns.
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (a narrative review; follow-up periods of individual studies are not recorded).
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Having an atrial septal defect
- Excluded
- None stated
A 2025 open-access narrative review (Biomedicines) says an atrial septal defect is the most common congenital heart defect diagnosed in adulthood, and that ostium secundum defects are the most frequent type (about 80% of all ASDs). It says most children with an isolated defect have no symptoms, that signs of adverse effects increase with age, and that patients with an ASD have an increased risk of heart failure, stroke, atrial fibrillation and pneumonia and a reduced life expectancy, regardless of closure in childhood or adulthood.
Applies to Mixed recipients People with an atrial septal defect (2025 narrative review)
- Certainty method
- Not assessed
- Limitations
- A narrative review, not a trial and not a guideline; the statements come from its abstract and introduction, which cite other studies, and the review gives no effect size or follow-up time for them. The review is about heart rhythm disorders in ASD; its rhythm and electrocardiogram findings, its comparison of closed and open defects and its treatment options are not repeated. The atlas states no rule about testing for or closing a defect.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (8)
-
- Locator
- Abstract, para 1, sentence 1
- How it applies
- An ASD is the most common congenital heart defect diagnosed in adulthood.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
39ab9beb6b5c721cd478283f1fa853d7c413b15d47b264d5f86258b8881e6d77- Reuse basis
- PMC Open Access subset article under the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/, content-type ccbylicense, CC BY 4.0). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
- Locator
- 1. Introduction, para 1, sentence 2 (end)
- How it applies
- Ostium secundum defects are the most frequent type, about 80% of all ASDs.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
39ab9beb6b5c721cd478283f1fa853d7c413b15d47b264d5f86258b8881e6d77- Reuse basis
- PMC Open Access subset article under the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/, content-type ccbylicense, CC BY 4.0). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
- Locator
- 1. Introduction, para 2, sentence 1 (first part)
- How it applies
- Most children with an isolated ASD are asymptomatic.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
39ab9beb6b5c721cd478283f1fa853d7c413b15d47b264d5f86258b8881e6d77- Reuse basis
- PMC Open Access subset article under the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/, content-type ccbylicense, CC BY 4.0). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
- Locator
- Abstract, para 1, sentence 3 (first part)
- How it applies
- Signs of adverse effects of an ASD increase with age.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
39ab9beb6b5c721cd478283f1fa853d7c413b15d47b264d5f86258b8881e6d77- Reuse basis
- PMC Open Access subset article under the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/, content-type ccbylicense, CC BY 4.0). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
- Locator
- Abstract, para 1, sentence 3 (end)
- How it applies
- Risk of heart failure, stroke, atrial fibrillation and reduced life expectancy.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
39ab9beb6b5c721cd478283f1fa853d7c413b15d47b264d5f86258b8881e6d77- Reuse basis
- PMC Open Access subset article under the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/, content-type ccbylicense, CC BY 4.0). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
- Locator
- 1. Introduction, para 2, sentence 3 (first part)
- How it applies
- Increased risk of heart failure, stroke, atrial fibrillation and pneumonia.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
39ab9beb6b5c721cd478283f1fa853d7c413b15d47b264d5f86258b8881e6d77- Reuse basis
- PMC Open Access subset article under the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/, content-type ccbylicense, CC BY 4.0). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
- Locator
- 1. Introduction, para 2, sentence 3 (end)
- How it applies
- Reduced life expectancy regardless of closure in childhood or adulthood.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
39ab9beb6b5c721cd478283f1fa853d7c413b15d47b264d5f86258b8881e6d77- Reuse basis
- PMC Open Access subset article under the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/, content-type ccbylicense, CC BY 4.0). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
Background MeSH scope note for descriptor D006344 (Heart Septal Defects, Atrial)
- Locator
- scopeNote.@value, sentence 1
- How it applies
- MeSH scope note: what an atrial septal defect is.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
54a7988482244b2931e2f96f0a4148e96f3296ffb95902af39c8f29e7b7721d0- Reuse basis
- The NLM web policies page (sha256 c8b7026b5c3fcfd1b0cb88755077f6a99a5f2159eecd42b0e7d1a5ad9b30ec55, hash only) says works produced by the U.S. government are not subject to copyright protection in the United States and asks users to acknowledge NLM as the source. The NLM MeSH terms and conditions page (sha256 f33b14141a5b6c8a2b1464c751dbdbb0a0d476c913851bf2a8c3d5c14b1afce7, hash only) asks redistributors to maintain current data or to make known that their copy may not reflect the most current data. This copy was fetched on 2026-11-18 and may not reflect the most current data. The raw bytes are committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact A 2025 review lists atrial fibrillation among the risks in people with an atrial septal defect: Atrial fibrillation (AF)
Applies to Mixed recipients People with an atrial septal defect (2025 narrative review)
A 2025 open-access narrative review (Biomedicines) says an atrial septal defect is the most common congenital heart defect diagnosed in adulthood, and that ostium secundum defects are the most frequent type (about 80% of all ASDs). It says most children with an isolated defect have no symptoms, that signs of adverse effects increase with age, and that patients with an ASD have an increased risk of heart failure, stroke, atrial fibrillation and pneumonia and a reduced life expectancy, regardless of closure in childhood or adulthood.Limitations. A narrative review, not a trial and not a guideline; the statements come from its abstract and introduction, which cite other studies, and the review gives no effect size or follow-up time for them. The review is about heart rhythm disorders in ASD; its rhythm and electrocardiogram findings, its comparison of closed and open defects and its treatment options are not repeated. The atlas states no rule about testing for or closing a defect.
-
Claim, not a settled fact A 2025 review lists heart failure among the risks in people with an atrial septal defect: Heart failure
Applies to Mixed recipients People with an atrial septal defect (2025 narrative review)
A 2025 open-access narrative review (Biomedicines) says an atrial septal defect is the most common congenital heart defect diagnosed in adulthood, and that ostium secundum defects are the most frequent type (about 80% of all ASDs). It says most children with an isolated defect have no symptoms, that signs of adverse effects increase with age, and that patients with an ASD have an increased risk of heart failure, stroke, atrial fibrillation and pneumonia and a reduced life expectancy, regardless of closure in childhood or adulthood.Limitations. A narrative review, not a trial and not a guideline; the statements come from its abstract and introduction, which cite other studies, and the review gives no effect size or follow-up time for them. The review is about heart rhythm disorders in ASD; its rhythm and electrocardiogram findings, its comparison of closed and open defects and its treatment options are not repeated. The atlas states no rule about testing for or closing a defect.
-
Claim, not a settled fact A 2025 review lists stroke among the risks in people with an atrial septal defect: Stroke
Applies to Mixed recipients People with an atrial septal defect (2025 narrative review)
A 2025 open-access narrative review (Biomedicines) says an atrial septal defect is the most common congenital heart defect diagnosed in adulthood, and that ostium secundum defects are the most frequent type (about 80% of all ASDs). It says most children with an isolated defect have no symptoms, that signs of adverse effects increase with age, and that patients with an ASD have an increased risk of heart failure, stroke, atrial fibrillation and pneumonia and a reduced life expectancy, regardless of closure in childhood or adulthood.Limitations. A narrative review, not a trial and not a guideline; the statements come from its abstract and introduction, which cite other studies, and the review gives no effect size or follow-up time for them. The review is about heart rhythm disorders in ASD; its rhythm and electrocardiogram findings, its comparison of closed and open defects and its treatment options are not repeated. The atlas states no rule about testing for or closing a defect.
-
Claim, not a settled fact Evaluated for this: Closure of atrial septal defect and patent foramen ovale
Applies to Recipient not specified People having an atrial septal defect closed (2023 device review)
Population, setting and follow-up
- People whose atrial septal defect is closed through a catheter, as the review describes them. It also covers some patients with a patent foramen ovale, and the comparison with surgery.
- Catheterization laboratory, as the review describes the procedure. Surgery is mentioned only as a comparison.
- The review discusses United States device approvals; this record does not use them.
- Not restricted in the abstract or introduction. The review includes studies of adults and of children; this record makes no statement about newborns, pregnancy or any age group.
- Gestational age Not reported
- Postnatal age Not reported
A 2023 open-access narrative review of devices for transcatheter closure of atrial septal defect (Cureus) says transcatheter device closure is the preferred way of closing septum secundum defects. It says a meta-analysis found the transcatheter approach had a high success rate, lower rates of adverse events and shorter hospital stays compared with surgery, that complications have been reported but are relatively rare, and that careful patient selection and follow-up are necessary to minimize complications and ensure optimal outcomes. MedlinePlus lists cardiac catheterization to repair simple defects, such as a small hole in the inside wall of the heart, among the treatments for congenital heart defects.Limitations. A narrative review of devices, written in 2023; the outcome statements come from studies it cites, and its device list and trial figures are not repeated. The review mentions surgical closure only in comparison. The atlas states no rule about who should have a defect closed or by which route; the MedlinePlus sentence is general patient information.
-
Claim, not a settled fact Evaluated for this: Amplatzer Septal Occluder
Applies to Recipient not specified United States PMA approval P000039: Amplatzer Septal Occluder for secundum atrial septal defect
Population, setting and follow-up
- Patients with echocardiographic evidence of an ostium secundum atrial septal defect and clinical evidence of right ventricular volume overload, and patients who have had a fenestrated Fontan procedure and now need the fenestration closed. The order gives no age range.
- Not stated in the FDA record
- United States (decision by the US Food and Drug Administration)
- Not stated in the FDA record
- Gestational age Not reported
- Postnatal age Not reported
The Amplatzer Septal Occluder is FDA-approved for closing atrial septal defects in the secundum position through a catheter, in patients with echocardiographic evidence of an ostium secundum defect and clinical evidence of right ventricular volume overload (a left-to-right shunt of 1.5 to 1 or right ventricular enlargement). The approval order also covers closing the fenestration after a fenestrated Fontan procedure. This states what the device is approved for. It is not a finding about how well the device works or how safe it is.Limitations. Describes the approval scope only. The order cited gives no age range, no trial results and no comparison with surgery; the summary of safety and effectiveness was not read. The link to adult congenital heart disease is the atlas's filing of the record: the approval does not say the patients are adults, and the NHLBI pages describe atrial septal defects as defects present at birth.
Record details
- Record id
cardio:atrial-septal-defect- Content hash
7444b676ea2b9bc769ca0c64cbd83465e95f3be3b9684fa2557b42181a4e8450